Skip to main content Skip to main navigation menu Skip to site footer

Analysis of eosinophil count as a predictor of Acute Lymphoblastic Leukemia (ALL)

  • Nefie Ilona Nurue ,
  • Darwati Muhadi ,
  • Mansyur Arif ,


Abstract

Background: Acute lymphoblastic leukemia (ALL) is a malignancy of blood cells in many children. Predicting the severity of ALL is important for treatment. An easy and cheap marker is eosinophil count. This study aims to analyze eosinophil count as a predictor of ALL severity.

Methods: Retrospective study using medical record data of 76 ALL patients from January 2020 to September 2021 was conducted at RSUP Dr. Wahidin Sudirohusodo Hospital. Patients are classified as ALL remission and relapses. Eosinophil Count based on routine blood test results using Sysmex XN-1000. Statistical Test using Kolmogorov-Smirnov test to assess data normality, Mann-Whitney test, eosinophil count diagnostic values analyzed with ROC curve to assess AUC and determination of cut-off value. The test results are significant if p<0.05.

Results: The sample consisted of 59 ALL remissions and 17 ALL relapses. The mean eosinophil was found to be significantly lower in the relapse patient (0.19) than in the Remission patient (0.47) (p<0.05). Based on the ROC curve, the value AUC = 0.660 and significant (p<0.05). This shows that the cut-off value of eosinophil count can be used as a prognostic value for the status of ALL patients. ROC curve shows the sensitivity and specificity of the eosinophil count is 70.6% and 54.2% at a cut-off of 0.15.

Conclusion: Eosinophil Count can be used as a prognostic value for the status of ALL patients with a cut-off value of 0.15. The eosinophil count was lower in the relapse patients than in the remission patients.

Keywords: ALL eosinophil count prognosis
Section

References

  1. Lightfoot T. Aetiology of childhood leukemia. Bioelectromagnetics. 2005; 26(S7):S5-S11.
  2. Kellerman J. Behavioral treatment of night terrors in a child with acute leukemia. J Nerv Ment Dis. 1979;167(3):182-185.
  3. American Cancer Society. Cancer facts & figures. 2016. [Accessed on 5th March 2023]. [Available at: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf]
  4. Kementerian Kesehatan RI. Infodatin Pusat Data dan Informasi Kementerian Kesehatan RI. 2016. [Accessed on 5th March 2023]. [Available at: http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatinkanke r.pdf]
  5. Chan KW. Acute lymphoblastic leukemia. Curr Probl Pediatr Adolesc Health Care. 2002;32(2):40-49.
  6. Kaneko H, Shimura K, Yoshida M, Ohkawara Y, Ohshiro M, Tsutsumi Y, et al. Acute lymphoblastic leukemia with eosinophilia lacking peripheral blood leukemic cell: a rare entity. Indian Journal of Hematology and Blood Transfusion. 2014;30(1):80-83.
  7. Andersen CL, Siersma VD, Hasselbalch HC, Vestergaard H, Mesa R, Felding P, et al. A association of the blood eosinophil count with hematological malignancies and mortality. American Journal of Hematology. 2015;90(3):225-229.
  8. Robison LL, Codd M, Gunderson P, Neglia JP, Anthony Smithson W, King FL. Birth weight as a risk factor for childhood acute lymphoblastic leukemia. Pediatric hematology and oncology. 1987;4(1):63-72.
  9. Angkasa YK, Suryawan N, Prihatni D. Clinical and Laboratory Manifestation of Children with Acute Lymphoblastic Leukemia as an Assessment of Severity: A Study in Dr. Hasan Sadikin General Hospital. Althea Medical Journal. 2019;6(2):65-70.
  10. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524.
  11. Hossain MJ, Xie L, McCahan SM. Characterization of pediatric acute lymphoblastic leukemia survival patterns by age at diagnosis. Journal of cancer epidemiology. 2014;1(1):1-9.
  12. Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, et al. Guideline for the investigation and management of eosinophilia. British Journal of Haematology. 2017;176(4):553-572.
  13. Shahriari M, Shakibazad N, Haghpanah S, Ghasemi K. Extramedullary manifestations in acute lymphoblastic leukemia in children: a systematic review and guideline-based approach of treatment. American Journal of Blood Research. 2020;10(6):360.
  14. Sari NKP, Mahartini NN, Mulyantari NK, Prawita AAAL, Krisnawati NK, Prabawa IPY, et al. Aberrant expression of CD5 in a B-lineage Acute Lymphoblastic Leukemia (ALL): a case report. Intisari Sains Medis. 2021;12(2): 473-476.
  15. Sari NM, Nurazizah NA, Lesmana R, Suryawan N, Susanah S. Retrospective Study on Very Early Relapse of Childhood Acute Lymphoblastic Leukemia at a Reference Centre in Indonesia. Bali Medical Journal. 2022;11(1):44–49.
  16. Kustiah, Hernaningsih Y. Acute Lymphoblastic Leukemia (B-ALL) with co-expression of CD33 and CD13. Bali Medical Journal. 2023;12(1):983-986.
  17. Prabawa IPY, Mahartini NN, Herawati S, Mulyantari NK. Acute Erythroleukemia (AML-M6) in one-year-old boy: a case report. Bali Medical Journal. 2022;11(3):1420–1425.

How to Cite

Nurue, N. I., Muhadi, D., & Arif, M. (2023). Analysis of eosinophil count as a predictor of Acute Lymphoblastic Leukemia (ALL). Indonesia Journal of Biomedical Science, 17(1), 100–103. https://doi.org/10.15562/ijbs.v17i1.444
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
50

Total
57

Share

Search Panel

Nefie Ilona Nurue
Google Scholar
Pubmed
IJBS Journal

Darwati Muhadi
Google Scholar
Pubmed
IJBS Journal

Mansyur Arif
Google Scholar
Pubmed
IJBS Journal